Tag Archives | BOLERO-2

Alpharadin may change standard of care for prostate cancer patients with bone mets

We recently attended the 2011 European Multidisciplinary Cancer Congress in Stockholm. Paradigm shifting data in breast cancer and advanced prostate cancer were presented at what turned out to be an excellent meeting in a charming, if expensive, city. Pieter Droppert (@3NT) has written several posts on biotech strategy blog about the exciting data for radium-223 […]

Continue Reading

Everolimus plus exemestane is the biggest advance in breast cancer since Herceptin

2011 European Multidisciplinary Cancer Congress Breast cancer news  There were two noteworthy breast trials with new data at the 2011 ESMO ECCO oncology congress in Stockholm this past weekend: 1) The phase III BOLERO-2 study for everolimus (Afinitor) plus exemestane is according to Sally Church, “probably the biggest single advance in breast since the Herceptin […]

Continue Reading

error: Content is protected !!